Female-led British biotech raises £2.4M to develop ‘smart bomb’ like drugs to kill cancer cells — TFN

Spirea Limited, a Cambridge-based biotech startup, has secured £2.4 million in funding from UK and US investors. The company develops a new generation of antibody-drug conjugate (ADC) treatments with a higher drug-to-antibody ratio, delivering more medicine to cancer cells. This innovative approach aims to create highly customized ADCs with improved efficacy and reduced side effects for treating solid tumors.

Spirea Raises £2.4 Million to Develop 'Smart Bomb' Cancer Drugs

Spirea Limited is a Cambridge-based biotech startup developing a new generation of antibody-drug conjugate (ADC) treatments. Their novel approach focuses on achieving a larger drug-to-antibody ratio, enabling the delivery of more medicine directly to cancer cells. This results in highly customized ADCs with improved efficacy and safety profiles for treating solid tumors.

A Cambridge-based biotech startup developing antibody-drug conjugate (ADC) treatments with a larger drug-to-antibody ratio for treating solid tumors.

3 years ago

Spirea Raises £2.4 Million to Develop 'Smart Bomb' Cancer Drugs

Covered on